Axsome Therapeutics is trading 4.35% up at $222 after reporting second-quarter revenue of $218.4 million, up 46% year over year, driven by Auvelity sales and the Alzheimer’s agitation launch.
- Revenue slightly missed estimates, while the $0.99 loss per share exceeded one consensus estimate.
- Investors appear focused on accelerating commercial growth, expanded sales capacity, and management’s reiterated path to cash-flow positivity.
- The move came despite a modestly weaker broader market, making the earnings update the clearest catalyst.